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Abstract Cell surface Fc receptors activate inflammation and are tightly controlled to prevent
autoimmunity. Antibodies also simulate potent immune signalling from inside the cell via the
cytosolic antibody receptor TRIM21, but how this is regulated is unknown. Here we show that
TRIM21 signalling is constitutively repressed by its B-Box domain and activated by phosphorylation.
The B-Box occupies an E2 binding site on the catalytic RING domain by mimicking E2-E3
interactions, inhibiting TRIM21 ubiquitination and preventing immune activation. TRIM21 is
derepressed by IKKb and TBK1 phosphorylation of an LxxIS motif in the RING domain, at the
interface with the B-Box. Incorporation of phosphoserine or a phosphomimetic within this motif
relieves B-Box inhibition, promoting E2 binding, RING catalysis, NF-kB activation and cytokine
transcription upon infection with DNA or RNA viruses. These data explain how intracellular




Antibodies are an essential component of protective immunity and their induction is a major aim of
vaccination. They mediate a sufficiently rapid inflammatory response upon pathogen re-exposure
that infection is halted before host colonization can occur. However, the consequences of inappro-
priate antibody-induced inflammation are severe, including lethal cytokine storms, autoimmunity and
chronic inflammatory disease (Suntharalingam et al., 2006). It is therefore essential that antibody
immunity is precisely regulated and tightly controlled. Antibody Fc receptors (FcRs) are essential for
the diverse effector responses mediated by antibodies (Woof and Burton, 2004). Classical FcRs are
expressed on the surface of immune cells. Their signalling induces phagocytosis, antigen presenta-
tion, antibody dependent cellular cytotoxicity (ADCC), degranulation and pro-inflammatory cytokine
production (Guilliams et al., 2014). Regulating FcR signalling controls the antibody response. FcR
immune signalling is influenced at multiple levels by; varying cell type expression and abundance,
balancing the activity of inhibitory vs activatory receptors, requiring receptor crosslinking, setting
minimal activation thresholds and by synergising with other pattern recognition receptors
(PRRs) (Vogelpoel et al., 2015). These diverse mechanisms, deciphered over many decades, operate
individually and synergistically to precisely regulate extracellular antibody immunity (Bruhns and
Jönsson, 2015).
Recent work from our lab has shown that, in addition to classical FcR immunity mediated at the
cell-surface, antibodies exert potent immune function from inside cells via a unique cytosolic IgG
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receptor called TRIM21 (James, 2014; Mallery et al., 2010; McEwan et al., 2013). TRIM21 is struc-
turally, functionally and evolutionarily distinct from surface FcRs and binds antibodies with a signifi-
cantly higher affinity (James et al., 2007). TRIM21 is also distinct in being constitutively and
ubiquitously expressed in most cell types and tissues. TRIM21 protects cells from pathogen infection
by stimulating a dual effector and sensor response. Upon infection, antibody-coated pathogens are
detected in the cytosol by TRIM21. TRIM21 recruits cellular degradation machinery, including the
AAA ATPase VCP and the proteasome, resulting in the destruction of viral particles and neutraliza-
tion of infection. TRIM21 simultaneously activates immune transcription pathways, including NF-kB,
leading to potent upregulation of pro-inflammatory cytokines including TNF, CXCL10, IL-6 and
IFN (McEwan et al., 2013). TRIM21 activation results in cytokine upregulation in mice within hours
of infection and is a significant component of the inflammatory response induced by protective
antibodies (Watkinson et al., 2015). Deletion of TRIM21 compromises the efficiency of protective
antibody immunity and causes virus-induced mortality (Vaysburd et al., 2013).
In contrast to cell-surface FcRs, and despite its capacity for such rapid and potent inflammatory
signalling, it is unclear exactly how TRIM21 is regulated. The regulatory mechanisms that exist for
classical FcRs are not applicable to TRIM21. TRIM21 is not expressed at the cell surface and there-
fore cannot be activated by clustering in lipid rafts or employ this as a mechanism to discriminate
monomeric IgG from immune complex. Furthermore, as TRIM21 is dimeric, it is capable of binding
both heavy chains of a single IgG simultaneously and forming a 1:1 complex. This is in contrast to
other FcRs, which bind asymmetrically to a single heavy chain. There is also no known complemen-
tary inhibitory receptor to TRIM21 as exist for surface FcRs. Finally, TRIM21 lacks the ITAM and ITIM
eLife digest Antibodies are molecules made by the immune system that protect us from
infections. They were discovered over 100 years ago, and for most of that time scientists thought
they only worked in the bloodstream. Yet recent research showed that when a virus infects our cells
it also carries antibodies in with it. Once inside the cell, a protein called TRIM21 recognises the
antibody-covered virus and – together with other proteins called ubiquitin enzymes – targets it for
destruction via the cell’s waste disposal system. At the same time TRIM21 sends a signal to the cell’s
nucleus to activate certain genes that protect cells across the body from subsequent infection.
The genes activated by TRIM21 have potent antiviral activity. Yet they can also damage the
body’s own tissues if they are switched on at the wrong time, which may lead to autoimmune
diseases like rheumatoid arthritis and multiple sclerosis. It is thus critical that TRIM21 is carefully
regulated and only activated during an infection, but it was not clear how this is achieved.
Dickson, Fletcher et al. now show that although TRIM21 is made all the time and is always ready
to detect an incoming virus it is made in an inactive state. This is because part of TRIM21, called a
B-Box, inhibits the protein’s own activity. This was an unexpected discovery because, although the
B-Box domain is found in around 100 other human proteins, it was unclear what it did. Dickson,
Fletcher et al. then combined structural biology and biochemical approaches to show that the B-Box
mimics specific enzymes that work with TRIM21, and blocks them from binding to it. This keeps
TRIM21 in an inactive state.
Next, Dickson, Fletcher et al. discovered that TRIM21 becomes active when a chemical tag,
specifically a phosphate group, is added to the protein. This modification displaces the B-Box,
allowing ubiquitin enzymes to bind to TRIM21 and switch on its activity. Further experiments then
showed that this process helps regulate TRIM21 during infections with different viruses, including
rhinovirus – the virus behind the common cold – and adenovirus – a common cause of respiratory
infection.
Antibodies are now used to treat many medical conditions, but present technologies are based
on our understanding of how antibodies work outside cells. By revealing the basis of antibody
immunity inside cells, these new findings may lead to new treatments for a range of conditions.
Future studies could also explore how failures in the TRIM21 system contribute to autoimmune
diseases.
DOI: https://doi.org/10.7554/eLife.32660.002
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motifs that drives the function of other FcRs, and whose signalling can be precisely regulated by
recruitment of Src family kinases and inositol-lipid phosphatases (Vogelpoel et al., 2015).
TRIM21 is a member of a large family of ~100 proteins with a common ‘tripartite motif’ architec-
ture, comprising N-terminal RING, B-Box and coiled-coil domains. Instead of recruiting Src and Syk
kinases, TRIM21 stimulates immune signaling via the activity of its RING domain, which catalyses the
synthesis of polyubiquitin chains. TRIM21 first recruits the E2 Ube2W to modify itself with an N-ter-
minal monoubiquitin (Fletcher and James, 2016). This acts as a primer for the synthesis of an
anchored K63-chain catalysed by the heterodimer Ube2N/2V2. TRIM21 is further modified with K48-
ubiquitin chains, culminating in proteasomal recruitment. The 19S-resident proteasomal deubiquiti-
nase Poh1 subsequently liberates K63 chains from TRIM21 (Fletcher and James, 2016), and these
then activate signal transduction pathways via TBK1, TAB/TAK and NEMO. We therefore hypothe-
sized that TRIM21 immune signaling must be regulated at the fundamental level of its ubiquitination
activity.
Here we show that initiating ubiquitination is a key step in regulating TRIM21 activity and that a
novel mechanism of autoinhibition and kinase-induced E2 enzyme recruitment controls its potent
pro-inflammatory activity.
Results
To investigate the regulation of TRIM21 we tested whether over-expression in the absence of anti-
body stimuli triggers NFkB. As a positive control, we compared its activity to that of TRIM5a, a
related antiviral TRIM protein whose over-expression is sufficient to drive spontaneous NFkB signal-
ling (Pertel et al., 2011). While transfection of full-length TRIM5a caused dose-dependent activation
of NFkB, full-length TRIM21 failed to activate NFkB at any dose (Figure 1A). When activated, both
TRIM21 and TRIM5a autoubiquitinate, thereby making themselves a degradative substrate for the
proteasome. Consistent with the NFkB result, while endogenous TRIM5a underwent rapid recycling
we found little evidence of TRIM21 turnover even after several hours (Figure 1B and Figure 1—fig-
ure supplement 1). Together these observations suggest either that TRIM21 is constitutively inactive
and its ubiquitination activity tightly regulated or it is a less active E3 ligase than TRIM5a. However,
comparing the ubiquitination activity of TRIM5a and TRIM21 isolated RING domains (T5-R or T21-R)
in vitro revealed that TRIM21 was the more active E3, capable of forming ubiquitin chains within
minutes (Figure 1C). RING dimerization via higher order assembly is the proposed mechanism by
which TRIMs autoregulate (Wagner et al., 2016). TRIM5a self-assembles and mutations that disrupt
RING dimerization inhibit catalytic ability (Yudina et al., 2015). We therefore introduced structurally
corresponding mutations into TRIM21 (Figure 1D and Figure 1—figure supplement 2) to test
whether RING dimerisation is required for activity. SEC MALS and AUC demonstrated that while the
wild-type RING is in monomer-dimer equilibrium, mutants M10E and M10E/M72E do not undergo
detectable dimerization (Figure 1E and F). However, both mutants remained active and could cata-
lyse unanchored K63 chain synthesis, Ube2W-primed anchored K63 chain extension and ubiquitin
discharge (Figure 1G–I), albeit less efficiently than wild-type. These results demonstrate that a pre-
formed TRIM21 RING dimer is not a pre-requisite for ubiquitination activity.
RING dimerization is not required for E2 enzyme binding, as all interactions occur within a single
monomer (Yudina et al., 2015). Instead, dimerization of RING E3s is thought to be needed for addi-
tional contacts with the E2-charged ubiquitin. Mutations in the partner RING at this interface reduce
TRIM25 catalytic activity in vitro (Figure 2A)(Sanchez et al., 2016). Equivalent mutations in TRIM21
had no impact on ubiquitination, confirming that RING dimerization is not an intrinsic requirement
for TRIM21 activity (Figure 2B–D). The mutation E10R reduces ubiquitination by TRIM25, possibly
by disrupting a hydrogen bond with ubiquitin (Koliopoulos et al., 2016). We hypothesised that the
corresponding glutamate (E13) in TRIM21 may allow a monomeric RING to contact both E2 and
bound ubiquitin simultaneously, obviating the requirement for dimerization. Consistent with this
hypothesis, E13R reduced TRIM21 catalysis (Figure 2D). Taken together these data show that the
monomeric TRIM21 RING is a highly active E3. Thus, the lack of constitutive TRIM21 NFkB activity
must be the result of tight regulation, independent of higher order oligomerisation.
The next domain in the tripartite motif of TRIM21 after the RING is the B-Box2 (hereafter referred
to as ‘B-Box’), a domain largely unique to TRIM proteins but whose function (besides an ability to oli-
gomerise in TRIM5a) is unknown. Comparing the activities of RING, RING-Box and MiniTRIM21
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Figure 1. TRIM21 NFkB signalling is constitutively silent despite monomeric RING K63 chain synthesis. (A) TRIM5a (T5) but not TRIM21 (T21)
overexpression in 293Ts activates an NFkB-luciferase reporter. (B) Reduction in endogenous T5 and T21 protein levels after cycloheximide treatment.
(C) (left) Immunoblot for in vitro polyubiquitin synthesis catalysed by T5 or T21 RING (R) domains in the presence of Ube2N/Ube2V2; (right) SDS-PAGE
showing T21 R autoubiquitination in the presence of Ube2W and Ube2N/Ube2V2. (D) RING dimerization interface in T5 structure (4TKP). (E–F)
Oligomerisation of T21 R and mutants M10E and M10E/M72E as assessed by (E) SEC MALS and (F) AUC. (G–H) Wild-type (WT) T21 R or dimerization
mutants catalyzing unanchored polyubiquitin synthesis using Ube2N (G) or anchored chains using Ube2N/Ube2V2 and Ube2W (H). (I) T21 (WT or
mutants) catalysed discharge of ubiquitin from conjugated Ube2N/Ube2V2.
DOI: https://doi.org/10.7554/eLife.32660.003
The following figure supplements are available for figure 1:
Figure supplement 1. Cellular Turnover of endogenous TRIM5a and TRIM21.
DOI: https://doi.org/10.7554/eLife.32660.004
Figure supplement 2. Sequence alignment of TRIM5 and TRIM21.
DOI: https://doi.org/10.7554/eLife.32660.005
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proteins (based on a monovalent MiniTRIM5 that preserves the Box-coiled coil
interface (Wagner et al., 2016)), revealed that the presence of the B-Box significantly reduces ubiq-
uitination (Figure 3A). This is due to direct inhibition of catalytic activity, as the B-Box prevented
ubiquitin discharge from either Ube2D1 or Ube2N (Figure 3B). To understand how the B-Box modu-
lates TRIM21 catalysis we solved a 2 Å crystal structure of the RING-Box protein
(Supplementary file 1). Surprisingly, this revealed that the B-Box occupies the E2 binding site on
the RING domain (Figure 3C). Comparison to the TRIM5a RING:E2 complex shows that the B-Box is
located where helix 1 of the E2 would normally be positioned during RING binding (Figure 3D). Cru-
cially, the B-Box is able to occupy the E2 binding site on the RING by acting as an E2 mimic, forming
similar electrostatic interactions. The RING surface contains a negatively charged patch, which is
complementary to a strongly positively charged patch on both the E2 and the B-Box (Figure 3E). In
particular, Box-RING interaction is stabilized through a salt bridge between residues R118 and E12,
which is analogous to the interaction between E2 residue R14 and RING residue E11 in the TRIM5:
Ube2N structure (Figure 3D). To test directly whether the B-Box prevents E2 binding we assigned
15N HSQC spectra of monomeric (M10E) RING and RING-Box constructs and measured chemical
shift perturbations (CSPs) upon titration with Ube2N (Figure 4 and Figure 4—figure supplement 1).
Titration of Ube2N into the RING resulted in significant CSPs in E2 interface residues (denoted by
the green shaded regions in Figure 4A). In contrast, no evidence of Ube2N binding to the RING-
Box was observed. Taken together, these data suggest that the B-Box may be an autoinhibitory
domain whose function is to regulate RING activity by preventing E2 recruitment.
Next, we investigated what relieves B-Box inhibition and promotes TRIM21 ubiquitination activity.
Recently it was shown that unrelated innate immune adaptors including MAVS, STING and TRIF all
contain a short pLxIS motif (where p is hydrophilic, x is non-aromatic and S is the target serine),
Figure 2. TRIM21 RING dimerization is not required to catalyse ubiquitin release from E2:Ub. (A) Model of the TRIM25 RING:Ube2N:Ub complex
(5EYA), showing interactions between ubiquitin and both RING monomers. (B–D) Ubiquitination activity of WT T21R and mutants of putative ubiquitin-
contacting residues in the second monomer. (B) Catalysis of unanchored ubiquitin chains using Ube2N. (C) Synthesis of anchored K63-chains on TRIM21
in presence of both Ube2N/Ube2V2 and Ube2W. (D) Catalysis of ubiquitin discharge from conjugated Ube2N/Ube2V2.
DOI: https://doi.org/10.7554/eLife.32660.006
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Figure 3. The Box is an autoinhibitory domain which supresses E3 ligase activity. (A) Catalysis of Ube2N/Ube2V2 driven polyubiquitin-chain synthesis by
T21 RING (R), RING-Box (RB) and MiniTRIM21 (MT). (B) T21 R or RB catalysed ubiquitin discharge from Ube2D1 or Ube2N. (C) 2 Å X-ray structure of T21
RB coloured by domain with zinc ions in cyan. (D) Superposition of T21 with T5 model 4TKP (grey), showing Ube2N and the Box are structurally
competitive. (E) Surface representation of (left-to-right) T21 R, Box and Ube2N binding sites coloured by electrostatic potential from  5 kT/e (red)
to + 5 kT/e (blue).
DOI: https://doi.org/10.7554/eLife.32660.007
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which recruits kinases IKKb or TBK1 resulting in serine phosphorylation and signal
potentiation (Liu et al., 2015). Remarkably, TRIM21 contains a very similar motif at the end of its
RING domain. Moreover, the target serine in this motif is located at the centre of the B-Box:RING
interface (Figure 5A) and undergoes phosphorylation in cells (Figure 5B). We hypothesized that this
could provide a mechanism to activate TRIM21 during an immune response. To investigate this fur-
ther, we raised specific antisera against the phosphoserine peptide 67RQLANMVNNLKEISQ81
(Figure 5C). Using this anti-pS80 serum, we detected cellular phosphorylation of TRIM21 but not an
S80A mutant, upon IKKb overexpression (Figure 5D). To ensure that IKKb was acting directly rather
than inducing the expression of a second kinase via NFkB, we repeated the experiment in the pres-
ence of proteasome inhibitor Bortezomib, which inhibits the degradation of IkBa and blocks NFkB
activation. Efficient IKKb phosphorylation of TRIM21 was observed even under conditions where
NFkB signaling was abolished (Figure 5E). To confirm that IKKb directly phosphorylates TRIM21, we
incubated recombinant RING-Box and IKKb proteins in vitro, observing ATP-dependent IKKb phos-
phorylation of TRIM21 that was lost upon mutation of motif residues or addition of an IKKb inhibitor
(Figure 5F–H). Robust IKKb-mediated phosphorylation was also observed using full-length TRIM21
protein (Figure 5I). Finally, knock-out of IKKb by CRISPR/Cas9 abolished modification of overex-
pressed TRIM21-His (Figure 5J), suggesting that endogenous kinase phosphorylates TRIM21.
Previously, it has been shown that while MAVS is phosphorylated by IKKb and TBK1, STING and
TRIF are only phosphorylated by TBK1 suggesting that there is differential kinase dependence even
though signaling adapters share the consensus pLxIS motif (Liu et al., 2015). To test whether
TRIM21 is a substrate for TBK1 phosphorylation, we incubated the recombinant full-length protein
with the kinase in the presence of ATP. TBK1 was capable of phosphorylating TRIM21 in vitro
Figure 4. The Box prevents binding of E2 enzyme to the RING E3. (A) Chemical shift perturbations recorded upon addition of unlabelled
Ube2N into 15N labelled TRIM21 RING (R) (top) or RING-Box (RB) (bottom). E2 interacting regions are highlighted in green and secondary structure
elements comprising either helices (rectangles) or b-strands (arrows) are indicated at the top of each plot. (B) Examples of the 15N HSQC spectra;
residues in the RING (top) are shifted upon adding E2 (RING:E2 ratio: black 1:0, blue, 1:0.5, red, 1:1), while the same residues in the RING-Box
(bottom) show little or no movement at a 1:1 titration point (red). Figure 4—figure supplement 1 shows the complete spectra.
DOI: https://doi.org/10.7554/eLife.32660.008
The following figure supplement is available for figure 4:
Figure supplement 1. HSQC of TRIM21 RING and RING-Box with Ube2N.
DOI: https://doi.org/10.7554/eLife.32660.009
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comparably with IKKb (Figure 6A). Overexpressed TBK1 was also capable of strongly phosphorylat-
ing cellular TRIM21 and causing significant stabilization of the protein (Figure 6B). To overcome limi-
tations of kinase overexpression we sought to stimulate TRIM21 phosphorylation by activing the
upstream pathway. First, we stimulated the TBK1 pathway by expressing one of its upstream adap-
tors, MAVS. MAVS expression significantly increased phosphorylation of TRIM21 (Figure 6C).
Figure 5. TRIM21 possesses a pLxxIS motif in its RING domain and is phosphorylated in vitro and in cells. (A) Residue S80 (yellow spheres) is located at
the centre of the Box:RING interface and is part of an epitope related to the IKKb phosphorylation motif found in TRIF. (B) MS/MS spectra of TRIM21-
His purified from 293 T cells indicating the presence of phosphorylated S80 (pS80) within a tryptic peptide precursor/m/z/680.0̂3 ± 0.39 ppm. (C) ELISA
of pS80 antisera at 1:50000 against recombinant WT or pS80 TRIM21. (D) IKKb phosphorylates C-terminally His-tagged WT but not S80A T21-His, as
detected by specific pS80 polyclonal sera. (E) As D except in presence of 30 nM bortezomib (Btzb) or DMSO and, below, NFkB stimulation by IKKb in
parallel. (F–H) In vitro phosphorylation of T21 RB by IKKb with increasing ATP (F), impaired phosphorylation of S80A and I79R RB (G), in presence of 20
mM IKKb inhibitor TPCA-1 (H). (I) In vitro IKKb phosphorylation of full-length lipoyl-T21. (J) Phosphorylation of WT or S80A T21-His from control 293T
(spCas9) or IKKb-deleted 293T (spCas9/sgIKKb) cells.
DOI: https://doi.org/10.7554/eLife.32660.010
Dickson et al. eLife 2018;7:e32660. DOI: https://doi.org/10.7554/eLife.32660 8 of 22
Research article Structural Biology and Molecular Biophysics
Second, we stimulated cells with the MDA5/RIG-I ligand poly(I:C) (Kato et al., 2008). We observed
a rapid increase in TRIM21 phosphorylation upon poly(I:C) stimulation, consistent with TBK1 activa-
tion (Figure 6D). Finally, we monitored changes in TRIM21 phosphorylation following infection with
antibody-coated adenovirus, under conditions where we have previously demonstrated TRIM21-
dependent antiviral activity (McEwan et al., 2013). The data show that in equivalent levels of immu-
noprecipitated TRIM21 there is a significant increase in the proportion of phosphorylated TRIM21
(Figure 6E).
We next investigated whether serine phosphorylation can act as a switch to relieve B-Box inhibi-
tion and activate TRIM21. To test this, we introduced the phosphomimetic mutation S80E into the
RING-Box and measured its ability to catalyse ubiquitin discharge. Remarkably, introduction of S80E
into the RING-Box was sufficient to completely restore catalytic activity to the same level as the
RING alone (Figure 7A–B). While glutamate is a routinely used phosphomimetic it does not fully
recapitulate a phosphoserine. We therefore utilized an evolved orthogonal aminoacyl-tRNA synthe-
tase/tRNACUA pair (Rogerson et al., 2015) to incorporate phosphoserine co-translationally at posi-
tion 80 in MiniTRIM21 protein. Comparison with wild-type protein revealed that S80
phosphorylation potentiates TRIM21 ubiquitination activity (Figure 7C). Phosphorylation-depen-
dence was confirmed by treating the phosphoprotein with phosphatase, which dephosphorylated
S80 and restored autoinhibition (Figure 7C). Taken together, this show that modification of S80 is
sufficient to control ubiquitination activity of TRIM21 in the presence of the B-Box. Moreover, mutant
S80E can be used as a functional mimic of serine phosphorylation at position 80.
The above data suggest that TRIM21 is kept in a constitutively inactive state by the B-Box
domain, which prevents E2 binding and whose autoinhibition is released upon phosphorylation. To
test this, we compared NFkB activation by TRIM21 mutants S80E or S80A with TRIM5a. Neither
S80A nor wild-type TRIM21 triggered NFkB, but S80E conferred robust activation (Figure 8A). In
contrast, mutation of residue S80 did not alter virus neutralization (Figure 8B). This is consistent with
previous data that TRIM21 signalling has an activation threshold whereas neutralization does
not (Foss et al., 2016). To demonstrate the importance of TRIM21 phosphorylation in immune sens-
ing during infection, we challenged cells expressing different TRIM21 mutants with human adenovi-
rus (Adv) ± human serum IgG and measured TNFA transcription after 4 hr. Significant TNFA
induction was only observed during infection in the presence of antibody, and not in TRIM21 knock-
out cells (K21, Figure 8C and Figure 8—figure supplement 1). Normal TNFA induction was
Figure 6. TRIM21 is phosphorylated upon immune stimulation. (A) Full-length recombinant lipoyl-T21 protein phosphorylation in vitro by IKKb and
TBK1. (B–C) Expression of TBK1 (B) or upstream adaptor MAVS (C) in 293 T cells phosphorylates and stabilises C-terminally His-tagged T21. (D) 293 T
cells lacking T21 reconstituted with His-tagged T21 and challenged with poly(I:C). Increased phosphorylation of T21 detected by immunoblot with pS80
antisera. (E) As in (D), except cells infected with adenovirus 5 (AdV) in the presence of IgG and T21 immunoprecipitated 7 hr post-infection.
DOI: https://doi.org/10.7554/eLife.32660.011
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Figure 7. Phosphorylation of S80 or phosphomimetic mutation S80E releases Box inhibition and promotes TRIM21 ubiquitination activity. (A–B)
Catalysis of ubiquitin discharge from Ube2D1 (A) or Ube2N (B) by TRIM21 RING (R), RING-Box (RB) or RING-Box containing S80E mutation. The
phosphomimetic mutation is sufficient to confer RING-like discharge kinetics on the RING-Box (offset graphs). (C) (top) Ubiquitin-chain catalysis by
MiniTRIM21 either WT or with a phosphoserine incorporated co-translationally at position 80 by amber suppression (pS80). WT and pS80 MiniTRIM21
blotted with pS80 or T21 sera (top-right) or after treatment with lambda protein phosphatase (LPP) (bottom-right). LPP dephosphorylates S80 and
restores Box autoinhibition.
DOI: https://doi.org/10.7554/eLife.32660.012
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restored in K21 cells by TRIM21 overexpression, confirming TRIM21-dependence. Importantly,
expression of S80A failed to rescue TNFA induction, while S80E enabled TNFA induction beyond
wild-type levels. A change in TRIM21 phosphorylation upon infection could not be detected but this
may be because only a fraction of cellular TRIM21 is recruited and modified during the response.
This would be consistent with previous data showing that TRIM21 ubiquitination and degradation is
also undetectable, despite being required for activity(Mallery et al., 2010). To confirm the impor-
tance of S80 and B-Box inhibition in regulating TRIM21 immune signaling, we repeated our infection
experiments using an unrelated RNA virus, human rhinovirus 14 (HRV). As with AdV, expression of
wild-type TRIM21 in knockout cells increased TNFA induction upon infection with HRV + antibody
Figure 8. B-Box autoinhibition regulates antibody-dependent immune signalling by TRIM21. (A) NFkB activation in 293Ts expressing WT, S80A or S80E
T21 or WT T5. Phosphomimetic mutation S80E is sufficient to render TRIM21 constitutively active for NFkB activity. (B) Adenoviral neutralization is
reconstituted in T21 knockout MEFs (K21) equally upon overexpression with WT or S80 mutants. (C) T21-mediated TNFA induction upon adenoviral
(AdV) infection in the presence of antibody (Ab) is restored in K21 by overexpression of WT TRIM21 but not S80A, while S80E is hyperactive. Fold
change in TNFA transcripts as determined by qPCR. (D) Immune gene transcription induced by antibody-coated human rhinovirus (HRV) in
reconstituted MEFs. Phosphomimetic mutation S80E potentiates transcriptional activation by TRIM21, while S80A inhibits activity.
DOI: https://doi.org/10.7554/eLife.32660.013
The following figure supplement is available for figure 8:
Figure supplement 1. Ectopic expression of TRIM21 in knockout MEFs.
DOI: https://doi.org/10.7554/eLife.32660.014
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(Figure 8D). Mutant S80E greatly potentiated TNFA transcription while S80A failed to reconstitute
TRIM21 activity. Similar results were obtained for cytokines CXCL10 and IL6 and the interferon-stim-
ulated gene IFIT1.
To obtain direct evidence that S80 phosphorylation activates TRIM21 by displacing the B-Box
domain, we compared the E2 binding of wild-type and S80E RING-Box proteins by NMR. In contrast
to wild-type, we detected significant CSPs in canonical E2 binding site residues upon titration of
Ube2N into S80E (Figure 9A). There were also changes in residues at the base of helix 2, within the
linker and on B-Box residues that contact the RING. This is consistent with restoration of E2 binding
and the stabilization of an active conformation in which the B-Box domain is displaced. To further
demonstrate B-Box displacement, we compared the dynamics of wild-type and S80E proteins. The
{1H}15N NOE ratios reveal that the most dynamic region is the linker (residues 83–102) between the
RING and B-Box (Figure 9B). This is in agreement with the higher temperature factors observed for
these residues in the crystal structure (Figure 9—figure supplement 1). Importantly, mutant S80E
has markedly lower enhancement factors both in the linker region and in helix 1 (residues 1–17),
against which the B-Box packs (Figure 9B). This increase in local motion is consistent with reduced
interaction between RING and B-Box in the S80E mutant. To demonstrate that B-Box displacement
promotes access to the E2 binding site on the RING, we carried out paramagnetic relaxation
enhancement experiments (solvent PREs). In these experiments, addition of the paramagnetic metal
Figure 9. Phosphomimetic mutation S80E displaces the Box from the RING and allows E2 enzyme binding. (A) Comparison of chemical shift
perturbations upon E2 enzyme Ube2N titration into T21 RB (grey) or T21 RB S80E (black). E2 interacting regions are highlighted in green and secondary
structure is indicated by rectangles (helices) and arrows (b-strands). (B) Comparison of heteronuclear NOEs for T21 RB (grey) or T21 RB S80E (black) in
absence of E2. The data is consistent with increased dynamics in the linker region between the RING and the Box upon introduction of S80E. (C)
Relative solvent exposure in S80E vs. WT, as detected by solvent PREs (shown as intensity ratio WT/S80E mapped onto the RB structure; primary data in
Supplementary file 2). White areas indicate regions more solvent-exposed in WT while red areas indicate parts of the surface more solvent-exposed in
S80E.
DOI: https://doi.org/10.7554/eLife.32660.015
The following figure supplement is available for figure 9:
Figure supplement 1. Main chain temperature factors for T21 RING-Box structure.
DOI: https://doi.org/10.7554/eLife.32660.016
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complex Gd(DTPA–BMA) selectively attenuates signals from solvent-exposed surfaces
(Pintacuda and Otting, 2002). The S80E mutation caused a dramatic change in surface accessibility
precisely localized to the RING-Box interface (Figure 9C and Supplementary file 2). These data con-
firm that phosphomimetic mutation at serine 80 disrupts the RING:Box interaction and uncovers the
E2 binding site.
Discussion
Our results suggest intracellular antibody immune signalling is kept in check via tight regulation of
the cytosolic antibody receptor TRIM21. TRIM21 activates immune transduction pathways upon
sensing an antibody-coated pathogen by synthesizing K63-ubiquitin chains. Controlling synthesis of
these chains allows TRIM21 signalling to be regulated at the fundamental level. Here we have shown
that this is accomplished by keeping TRIM21 in a constitutively silent state through an autoinhibitory
mechanism that blocks E2 enzyme recruitment. Autoinhibition is mediated by the B-Box, providing a
function for this ubiquitous but hitherto enigmatic TRIM protein domain. The B-Box inhibits E2
recruitment by acting as an E2 mimic and competing for RING binding. We also show that TRIM21
contains a variant of an IKKb and TBK1 phosphorylation motif and is phosphorylated at residue S80.
Phosphorylation of S80 or its replacement by a phosphomimetic displaces the B-Box, allowing E2
recruitment and potentiating TRIM21 ubiquitination activity, NF-kB signalling and cytokine transcrip-
tion upon infection with DNA or RNA viruses.
Although TRIM21 regulation is seemingly distinct from that of cell-surface FcRs, parallels exist.
For instance, signalling by both types of antibody receptor involves regulation by kinases. In the
case of TRIM21, this involves a pLxxIS motif (where p is hydrophilic) and the kinases IKKb and TBK1
while in other FcRs this involves an YxxL/I motif and recruitment of Src kinases. Importantly, it is not
clear for either receptor type exactly how kinase activation occurs. For surface FcRs, this is thought
to involve receptor clustering via cross-linking but why this causes Src recruitment and activation is
unclear (Huang et al., 1992). TRIM21 may also undergo clustering, via cross-linking or higher order
assembly, when it is recruited to opsonized pathogens. This may provide a basal activity that is
amplified by kinase phosphorylation. The co-option of IKKb and TBK1 as amplifying kinases suggests
that TRIM21 could participate in its own positive-feedback loop. Again there are parallels to surface
FcRs, where tyrosine phosphorylation has been shown to promote receptor clustering, which pro-
motes phosphorylation and so on (Sobota et al., 2005).
Both types of Fc receptor also synergise with other PRRs and immune signalling pathways to
amplify and diversify the resulting inflammatory response. Surface FcRs are known to exhibit cross-
talk with Toll-like receptors (TLRs), greatly amplifying the production of cytokines such as TNFa dur-
ing phagocytosis of opsonized bacteria (den Dunnen et al., 2012; Vogelpoel et al., 2014). Similarly,
TRIM21 has been shown to synergise with cytosolic nucleic acid receptors such as RIG-I and cGAS,
resulting in pathogen-specific responses and multiple signalling waves (Watkinson et al., 2015).
Whether there is direct collaboration between TRIM21 and surface FcRs is currently unknown and
will be important to determine in future work. Both immune signalling and antigen processing func-
tions of TRIM21 are well placed to synergise with FcR immune complex capture and sorting activi-
ties, for instance to promote class I presentation. Precedence exists in the form of collaboration
between FcRn and surface FcRs to drive antigen processing by dendritic cells (DCs)(Baker et al.,
2011; Qiao et al., 2008).
TRIM21 belongs to a large family of structurally related proteins, many of which have known roles
in cell signalling. They include other proteins with roles in immune signalling, such as the antiretrovi-
ral TRIM5(14) and RIG-I activator TRIM25 (Gack et al., 2007). While progress has been made in
understanding the structure and function of TRIMs, it is still unclear how TRIM proteins are activated
and regulated. Existing models of activation were solely based on substrate-induced aggregation or
higher order assembly. This was thought to be necessary for dimerization of the RING domains
located at either end of the molecule, which was assumed to be a pre-requisite for ubiquitination
activity (Koliopoulos et al., 2016). However, our data show that this is not the case for TRIM21, and
so cannot be assumed for other members of the TRIM family. Furthermore, higher order assembly
alone does not explain the discrepancy between in vitro and cellular TRIM ubiquitination activity.
TRIM RINGs, including those of TRIM5, 25 and 32, are active in vitro at concentrations where they
are monomeric (Yudina et al., 2015; Sanchez et al., 2016; Koliopoulos et al., 2016). Given that
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TRIMs are not constitutively active in cells, there must be another level of regulation. It has been pro-
posed that binding of a ubiquitin-conjugated E2 may drive RING equilibrium towards the dimeric
form, explaining the in vitro activity. However, this would not explain the absence of activity in cells
where the same phenomenon would occur. Moreover, if E2-Ub can drive TRIM RING dimerization
then a pre-existing dimer is by definition no longer a pre-requisite for function and higher order
assembly cannot be the sole regulator. It seems likely that the activation and regulation of TRIMs is a
complex process that is regulated at multiple levels. This is exemplified by TRIM21 whose neutraliza-
tion and signalling functions are both mediated by ubiquitination, but only signalling requires release
of B-Box inhibition. Previously we have observed that TRIM21 signalling has a distinct threshold
whereas neutralization takes place at very low antibody occupancy (<2 antibodies) (McEwan et al.,
2012) and under conditions of sub-optimal TRIM21:antibody and antibody:antigen
kinetics (Foss et al., 2016; Bottermann et al., 2016). Therefore, basal activity via higher order
assembly may be sufficient for neutralization but not signalling. Strict regulation of signalling is intui-
tive, as it ensures a proportional response and avoids inappropriate triggering. Setting activation
thresholds and regulating signalling may mitigate against any endosomal leakage of antibodies into
the cytosol. The activation of TRIM21 by leaked immune complexes in lysosome-maturation-defec-
tive macrophages of lupus-prone mice illustrates the consequences of such an
event (Monteith et al., 2016). However, while the requirement for tight regulation of TRIM21 signal-
ling is intuitive the mechanism behind this has remained elusive. Our data suggest that it is achieved
by a novel autoinhibitory mechanism in which the B-Box domain prevents ubiquitination by acting as
an E2 mimic and the kinases IKKb and TBK1 promote ubiquitination by phosphorylating the RING to
relieve B-Box inhibition. Use of innate immune kinases intimately associates TRIM21 with the antiviral
state not only at the level of gene expression as an ISG but also post translationally and in a similar
manner to key immune adaptors MAVS, STING and TRIF (Liu et al., 2015).
Materials and methods
Cloning, expression and purification of recombinant proteins
Ube1, Ube2N, Ube2V2, Ube2D1, TRIM21RING-Box (residues 1–129) were produced as previously
described (Fletcher et al., 2015). TRIM21RING (residues 1–85), TRIM5aRING (residues 1–88) and
Ube2W were sub-cloned into pOP-TG for expression with a TEV cleavable GST tag. Point mutations
were introduced using the site-directed mutagenesis protocol of Liu and Naismith (Liu and Nai-
smith, 2008). Gibson cloning was used to remove the N-terminal GST tag and introduce a non-
cleavable C-terminal STREP tag (Gibson et al., 2009). The miniTRIM21 construct was designed using
the strategy of (Wagner et al., 2016). Residues 225–265 of a bacterial seryl-RNA synthetase, encod-
ing an anti-parallel coiled-coil hairpin was inserted between two regions of the TRIM21 N-terminus,
including residues 1–154 (RING-B-Box-coil) and residues 221–260 (coil). The resulting gene was
cloned into pOP-TG for expression with a TEV cleavable GST tag at the N-terminus.
The Escherichia coli strain C41, was used for recombinant protein expression. Cells were grown in
2TY media supplemented with 100 mg/mL ampicillin at 37˚C until an OD600 of 0.7. The cells were
induced with 1 mM IPTG and incubated over-night at 18˚C. For expression of TRIM proteins, 1 mM
IPTG was included upon induction. After harvesting, cells were resuspended in 50 mM Tris pH 8,
150 mM NaCl, 10 mM ZnCl2, 1 mM DTT, 20% (vol/vol) Bugbuster (Novagen) and cOmplete protease
inhibitors (Roche, Switzerland). The cell suspension was lysed by sonication, clarified by centrifuga-
tion at 18000 rpm for 40 min and passed over glutathione-sepharose resin (GE Healthcare). The
fusion proteins were cleaved with TEV protease overnight at 4˚C and were left with an N-terminal
scar consisting of the tripeptide, Gly-Ser-His. Size exclusion chromatography was carried out on a
High load 26/60 Superdex 75 prep grade column (GE Healthcare) as final purification step. All pro-
teins were stored in 50 mM Tris pH 8, 150 mM NaCl, 1 mM DTT.
Isotopically labeled TRIM21RING-M10E, TRIM21RING-Box-M10E, TRIM21RING-Box-M10E/M72E proteins
were produced in the Escherichia coli strain Rosetta 2(DE3). Cells were grown in K-MOPS minimal
medium supplemented with 20 mM 15NH4Cl and/or 0.4% [
13C]-glucose, 4 mM K3PO4 pH 8.0, vitamin
mix (0.1% Thiamine, 0.02% each d-Biotin, Choline chloride, Folic acid, Niacinamide, D-pantothenic
acid, Pyridoxal, 0.002% Riboflavin) and 100 mg/ml pantothillin. Expression and purification conditions
were as for unlabelled proteins, described above.
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Mass spectrometry
Polyacrylamide gel slices (1–2 mm) containing the proteins were prepared for mass spectrometric
analysis using the Janus liquid handling system (PerkinElmer, UK). Briefly, the excised protein gel
pieces were placed in a well of a 96-well microtitre plate and destained with 50% v/v acetonitrile
and 50 mM ammonium bicarbonate, reduced with 10 mM DTT, and alkylated with 55 mM iodoace-
tamide. After alkylation, proteins were digested with 6 ng/mL trypsin (Promega, UK) overnight at
37˚C. The resulting peptides were extracted in 2% v/v formic acid, 2% v/v acetonitrile. Digests were
analysed by nano-scale capillary LC-MS/MS using an Ultimate U3000 HPLC (ThermoScientific Dionex,
San Jose, USA) to deliver a flow of approximately 300 nL/min. A C18 Acclaim PepMap100 5 mm, 100
mm x 20 mm nanoViper (ThermoScientific Dionex, San Jose, USA), trapped the peptides prior to sep-
aration on a C18 Acclaim PepMap100 3 mm, 75 mm x 250 mm nanoViper (ThermoScientific Dionex,
San Jose, USA). Peptides were eluted with a 60 min gradient of acetonitrile (2% to 80%). The analyti-
cal column outlet was directly interfaced via a nano-flow electrospray ionisation source, with a hybrid
quadrupole orbitrap mass spectrometer (Q-Exactive Plus Orbitrap, ThermoScientific, San Jose,
USA). Data dependent analysis was carried out, using a resolution of 30,000 for the full MS spec-
trum, followed by ten MS/MS spectra. MS spectra were collected over a m/z range of 300–2000.
MS/MS scans were collected using a threshold energy of 27 for higher energy collisional dissociation
(HCD). LC-MS/MS data were then searched against a protein database (UniProt KB) using the Mas-
cot search engine programme (Matrix Science, UK) (Perkins et al., 1999). Database search parame-
ters were set with a precursor tolerance of 10 ppm and a fragment ion mass tolerance of 0.8 Da.
One missed enzyme cleavage was allowed and variable modifications for oxidized methionine, car-
bamidomethyl cysteine, pyroglutamic acid, phosphorylated serine, threonine and tyrosine, ubiquity-
lation at lysine and the N-terminus were included. MS/MS data were validated using the Scaffold
programme (Proteome Software Inc., USA). All data were additionally interrogated manually.
Analytical ultracentrifugation
Samples of TRIM21RING, and mutants TRIM21RING-M10E and TRIM21RING-M10E/M72E at concentrations
of 7.5 mg/ml were subjected to velocity sedimentation at 50,000 rpm at 20 ˚C in 50 mM Tris-HCl, pH
8.0, 150 mM NaCl, 1 mM DTT using 12 mm double sector cells in an An50Ti rotor using an Optima
XL-I analytical ultracentrifuge (Beckmann). The sedimentation coefficient distribution function, c(s),
was analyzed using the SEDFIT program, version 14.0 (Schuck, 2003). The partial-specific volumes
(v-bar), solvent density and viscosity were calculated using Sednterp (Dr. Thomas Laue, University of
New Hampshire).
SEC-MALLS
Size-exclusion chromatography (SEC) was performed with inline multi-angle laser light scattering
(MALLS) using a Wyatt HELEOS-II 18-angle photometer coupled to a Wyatt Optilab rEX differential
refractometer (Wyatt Technology Corp). Samples of 100 mL were injected at 19.5 mg/mL and sepa-
rated over a Superdex 75 10/300 GL (GE Healthcare) equilibrated in 50 mM Tris, pH 8, 150 mM
NaCl, 1 mM DTT.
In vitro ubiquitination assay
In vitro ubiquitination reactions were carried out in 50 mM Tris at pH 8, 2.5 mM MgCl2, 0.5 mM DTT
with 0.2 mM Ub, 2 mM ATP, 1 mM Ube1, 0.5 mM Ube2N, 0.5 mM Ube2V2 1.5 or 1 mM TRIM21
RING-Box or RING protein respectively. The reaction was started upon incubation at 37˚C for the
time points indicated in the text. The reaction was stopped via the addition of LDS sample buffer at
4˚C, followed by boiling at 90˚C for 2 min. To observe the synthesis of TRIM21-anchored ubiquitin
chains, 1.5 mM Ube2w was included in the reaction. The reactions were resolved by LDS-PAGE and
TRIM21 or ubiquitin were detected by immunoblot using anti-TRIM21 [raised against human
TRIM21RING-Box or TRIM21RING], or anti-Ub-HRP (Santa Cruz, sc8017-HRP P4D1, 1:1,000).
Single-turnover ubiquitin discharge assay
To prevent auto-ubiquitination, lysine 92 of Ube2N was replaced with arginine (McKenna et al.,
2001). Ube2NK92R or Ube2D1 were loaded with ubiquitin by mixing 40 mM of the E2 with 1 mM
Ube1, 0.37 mM Ub and 3 mM ATP in 50 mM HEPES pH 7.5, 150 mM NaCl, 20 mM MgCl2, and
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incubating the reaction at 37˚C for 30 min. The reaction was transferred to ice and used immedi-
ately. To observe E3 mediated discharge of ubiquitin, 2 mM ubiquitin loaded E2 was mixed with 1.5
mM TRIM21RING-Box or TRIM21RING in 50 mM HEPES pH 7.5, 150 mM NaCl, 20 mM MgCl2, 50 mM
L-lysine. For discharge of ubiquitin from ubiquitin loaded Ube2N, 2.5 mM Ube2V2 was added to the
reaction. Samples were taken at the time points indicated in the text and mixed immediately with
LDS sample buffer at 4˚C. The samples were boiled for exactly 20 s, resolved by LDS-PAGE and
observed by immunoblot using anti-Ube2D (Boston Biochem, A-615, 1:1,000) or anti-Ube2N (Bio-
Rad, AHP974, 1:1,000). For Ube2N immunoreactivity was observed by near-infrared detection
(Odyssey, LI-COR).
Co-translational phosphorylation
Gibson cloning was used to sub-clone the TRIM21RING-Box and MiniTRIM21 sequences into the
pNHD1.3 plasmid (Rogerson et al., 2015) with the addition of a non-cleavable C-terminal Strep tag
(GSWSHPQFEK). An S80TAG mutation introduced using the site-directed mutagenesis protocol of
Liu and Naismith to create pNHD-T21RB(S80TAG) and pNHD-T21MT(S80TAG) (Liu and Naismith,
2008). Phosphorylated proteins were expressed in BL21 DserB(DE3) transformed with pKW2 EF-Sep
and pNHD-T21RB(S80TAG) or pNHD-T21MT(S80TAG). Cells were grown at 37˚C in TB media sup-
plemented with 25 mg/mL chloramphenicol and 25 mg/ml tetracycline. At OD600 = 0.6, the cells
were induced with 1 mM IPTG and 2 mM phosphoserine and incubated overnight at 18˚C. Cells
were harvested by centrifugation and resuspended in 100 mM Tris pH 8, 150 mM NaCl, 2 mM DTT,
10 mM ZnCl2, 20% (vol/vol) Bugbuster (Novagen) and Complete protease inhibitors (Roche). The cells
were lysed by sonication and centrifuged (18 000 rpm, 40 min, 4˚ C) to remove insoluble material.
The soluble lysates were applied to 5 mL of StrepTactin Sepharose High Performance resin (GE
Healthcare) that had been pre-equilibrated in wash buffer (100 mM Tris, pH 8, 150 mM NaCl, 1 mM
DTT). The resin was washed in 10 column volumes of wash buffer and the protein was eluted in wash
buffer with the addition of 2.5 mM D-desthiobiotin. Pooled protein fractions were subjected to size
exclusion chromatography over a High load 26/60 Superdex 75 prep grade column (GE Healthcare)
equilibrated in 50 mM Tris pH 8, 150 mM NaCl, 1 mM DTT. Incorporation of phosphoserine into the
recombinant protein was confirmed by ESI-MS or LC-MS/MS and western blot.
Dephosphorylation of recombinant phospho-proteins
Phosphorylated miniTRIM21 or the unmodified control were mixed with 400 U of Lambda protein
phosphatase and buffered with 1 X NEBuffer (50 mM HEPES, 100 mM NaCl, 2 mM DTT, 0.01% Birj
35, pH 7.5 @ 25˚C), supplemented with 1 mM MnCl2. The reactions were incubated at 30˚C for up
to 30 min with samples taken at the times indicated in Figure 4. Dephosphorylation was confirmed
by immunoblot using anti-TRIM21 and pS80 sera
In vitro kinase assay
In vitro phosphorylation reactions were carried out in 10 mL reactions with 50 mM Tris pH 7.4, 10
mM MgCl2, 0.5 mM DTT, 1 mM ATP, 430 ng IKKb (Life Technologies), 100 or 400 ng TBK1 (Prom-
ega), 1 mM TRIM21RING-Box or LipoylTRIM21, incubated at 37˚C for 2 hr, then quenched by addition
of LDS sample buffer and boiling at 95˚C for 5 min. Samples were resolved by LDS-PAGE and
TRIM21 detected by immunoblot using anti-TRIM21 (clone D12, Santa Cruz) or pS80 sera at 1:10000
and 1:1000 dilutions, respectively.
Cellular kinase assay
106293 T cells were transfected with 300 ng TRIM21-His (WT or S80A) and 3 mg empty vector or
IKKb (S177E/S181E). 48 hr later cells were washed, pelleted, denatured in 500 mL 6 M GuHCl, 0.1 M
Na2HPO4/NaH2PO4 (pH 8), 10 mM Imidazole (pH 8) and samples rotated for 3 hr at room tempera-
ture with 30 mL equilibrated NiNTA agarose (Qiagen). The agarose matrix was washed twice with
500 mL lysis buffer, twice with 500 mL 3:1 wash buffer:lysis buffer, once with 500 mL wash buffer (25
mM Tris, 20 mM imidazole pH 6.8), resuspended in 2  LDS sample buffer supplemented with 300
mM Imidazole to elute bound His-tagged proteins and heated for 5 min at 95˚C before LDS-PAGE.
For assaying IKKb activity in the absence of NF-kB signaling, 106293T were transfected with 500 ng
pGL4.32[luc2P/NF-kB-RE/Hygro], 200 ng TRIM21-His and 2 mg empty vector or IKKb. 6 hr later, cells
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were treated with DMSO or 30 nM bortezomib for 16 hr. Cells were washed, resuspended in 500 mL
cold PBS. 20 mL cells were mixed with 100 mL SteadyLite (Perkin Elmer) and luminescence measured
(Pherastar). The remaining cells were pelleted, denatured and mixed with NiNTA agarose as
described above. For TBK1 and MAVS transfection experiments, 200 ng TRIM21-His was transfected
with 2 mg empty vector or TBK1 or MAVS. Cells were harvested at 24 hr post transfection.
NF-kB reporter assay in 293T
293 T cells were seeded in 24 well plates 24 hr before transfection. Each well was transfected with,
typically, 5 ng TRIM cDNA, with 10 ng pGL4.32[luc2P/NF-kB-RE/Hygro] (NF-kB response element-
dependent firefly luciferase) and 5 ng pRL-TK (thymidine kinase promoter-dependent Renilla lucifer-
ase). 24 hr post transfection, cells were lysed in Passive Lysis Buffer and sequential firefly and renilla
luminescence measured (BMG Pherastar plate reader), according to manufacturers instructions
(Promega). Firefly luciferase luminescence was normalised to Renillia luciferase luminescence, and
these values normalised to those of empty vector transfected cells.
Generation of CRISPR knockout 293Ts
Single-guide RNA (sgRNA) against IKKb (GCTGACCCACCCCAATGTGG) was incorporated into the
Lenti CRISPR v2 plasmid (Addgene) and VSV-G pseudotyped lentiviral particles were generated by
three-plasmid transfection of 293T with Fugene-6 (Promega), using 1 mg HIV-1 Gag-Pol expression
plasmid, 1 mg VSV-G expression plasmid pMD2.G (GenScript), and 1.5 mg Lenti CRISPR v2 (IKKb), or
empty Lenti CRISPR v2 as a Cas9-encoding but sgRNA-negative control. 3  105 293T were trans-
duced with 50 mL 293T viral supernatant in the presence of 8 mg/mL polybrene (Santa Cruz), and
selected with 2.5 mg/mL puromycin. Single cell clones were derived by limiting dilution. Loss of pro-
tein expression was confirmed by immunoblot. Generation of TRIM21 knockout 293Ts (T21KO) was
achieved by electroporation (Neon) of Cas9/gRNA ribonucleoprotein complex (Cas9 RNP). The
recombinant Cas9-2NLS-GFP protein was produced as described (Jinek et al., 2012). Synthetic
tracrRNA and crRNA against TRIM21 (ATGCTCACAGGCTCCACGAA) were obtained from Sigma-
Aldrich. tracrRNA-crRNA complex was assembled by incubating at 20˚C for 10 min. The RNA com-
plex was combined with recombinant Cas9 protein at a molar ratio of 1:1.2 to form the Cas9 RNP
complex following an incubation at 37˚C for 10 min. Cas9 RNP against TRIM21 was introduced into
8  105 293 T cells using the Neon Transfection System (Invitrogen) with 2 pulses of 1400 V for 20
ms. 48 hr post electroporation the cells were cloned by fluorescence-activated cell sorting into 96-
well plates (1 cell/well). Loss of protein expression was confirmed by immunoblot. 293T/T21KO/
T21His were made by transducing T21KOs with T21His in pHR’.
Mice
C57BL/6 wild-type mice were obtained from Jackson Laboratories. Thirteen week old-mice were
used for immunisation experiment, which was conducted in accordance with the 19.b.6 moderate
severity limit protocol and Home Office Animals (Scientific Procedures) Act (1986). All animal work
was licensed under the UK Animals (Scientific Procedures) Act, 1986 and approved by the Medical
Research Council Animal Welfare and Ethical Review Body. Mice were immunised subcutaneously (s.
c) with 100 ug TRIM21 phophoS80-peptide (67RQLANMVNNLKEISQ81) conjugated to KLH in PBS
mixed with complete Freund’s adjuvant followed by 2 rounds of s.c boosting with 50 ug peptide
mixed with incomplete Freund’s adjuvant. Serum prepared from tail bleeds and cardiac blood was
analysed by ELISA for binding to pS80-TRIM21 or TRIM21.
Cells and viruses
WT and TRIM21-/- (K21) MEF cell lines were maintained in Dulbecco’s Modified Eagle Medium
(DMEM) supplemented with 10% fetal calf serum, penicillin at 100 U/ml and streptomycin at 100 mg/
ml. MEF cells were obtained from WT or TRIM21 knockout C57/B6 mice and have previously been
described and authenticated (Guilliams et al., 2014). Human adenovirus type five vector (DE1,DE3)
expressing GFP (AdV) was purchased from ViraQuest. Human rhinovirus type 14 (HRV) was produced
by infection of HeLa cells, and virus was purified by 2 rounds of CsCl centrifugation. 293T CRL-3216
cells were purchased from ATCC and authenticated by the supplier. All cells used are regularly
tested and are mycoplasma free.
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Poly(I:C) stimulation of 293T
107293T/T21KO/T21His were transfected with 25 ug/mL poly(I:C) using Lipofectamine LTX (Life
Technologies) and incubated for 5 or 10 min, or left untransfected. Cells were then washed, pelleted
and denatured in 500 mL 6 M GuHCl, 0.1 M Na2HPO4/NaH2PO4 (pH 8), 10 mM Imidazole (pH 8)
and pull-downs performed as in the ‘cellular kinase assay’ described above.
Adenovirus stimulation of TRIM21 phosphorylation
2.5  1011 pts/mL AdV vector was mixed with 10 mg/mL monoclonal anti-hexon 9C12 and incubated
for 1 hr at room temperature. 107293T/T21KO/T21His were transduced with virus/antibody mixture,
or treated with equal volume of PBS, and incubated at 37C for 7 hr. Cells were then washed, pel-
leted and denatured in 500 mL 6 M GuHCl, 0.1 M Na2HPO4/NaH2PO4 (pH 8), 10 mM Imidazole (pH
8) and pull-downs performed as in the ‘cellular kinase assay’ described above.
Lentiviral transduction
Human TRIM21 WT and mutants S80E, S80A were PCR amplified, cloned into lentiviral vector pHR’
(kind gift of Dr. Adrian Thrasher) using NotI and SalI restriction sites and sequence verified. Lentiviral
particles were generated by co-transfection of 10 cm2 dishes of 293Ts with 1 ug pCRV GagPol, 1 ug
pMD2G VSVg and 1.5 ug TRIM21 pHR’ using Fugene-6 (Promega). K21 MEF cells were infected with
lentivirus in the presence of 8 mg/mL polybrene and stably transduced cells were selected using
puromycin at 2 mg/ml. For the generation of stably expressed TRIM21-His, we cloned TRIM21-His
into pHR’, prepared lentivectors as above, transduced 293T TRIM21KO cells in the presence of 8
mg/mL polybrene, and selected cells with 2.5 mg/ml puromycin.
Cytokine analysis by qPCR
Cells were plated at 1  104 per well in 96 well plates. After 24 hr, viruses were mixed 1:1 with anti-
body and incubated for 30 mins at room temperature prior to infection. AdV was used at 1.25  109
pts per well mixed with 10 mg/ml human serum IgG (Sanquin). HRV was used at 2.5  102 TCID50
units per well mixed with 5 mg/ml human serum IgG (Sanquin). Cells were incubated at 37˚ C for 3.5
hr, before washing with PBS and preparation of cDNA using Cells to CT Kit (Ambion). Gene expres-
sion was monitored by TaqMan Gene Expression Assays (Applied Biosystems) on a StepOnePlus
Real Time PCR System (Life Technologies). Gene expression assays were: mouse b-actin (4352933E),
CxCL10 (Mm00445235_m1), TNF (Mm00443260_g1), IL-6 (Mm00446190_m1), IFIT1
(Mm00515153_m1). Relative expression was quantified using the 2 DDCt method.
Virus neutralization assay
Cells were seeded into 24-well plates at 5  104 cells/well and allowed to adhere overnight. Virus
was diluted to 1.5  108 pts in 6 ml in phosphate-buffered saline (PBS), mixed with an equal volume
of 9C12 antibody variant at the stated concentration, and incubated for 30 min to allow binding to
reach equilibrium. NAb-virus mixes were diluted 100-fold into cell culture medium and added to
cells. GFP-positive cells were analyzed by flow cytometry after 24 hr of incubation at 37˚C. Levels of
infection in the absence of NAb were in the range of 50% to 70%. Relative infection was calculated
by dividing the percent GFP-positive cells in the presence of antibody to that of a PBS-treated con-
trol infection.
Crystallography
TRIM21RING-Box protein at 10 mg/mL was buffer exchanged into 50 mM Tris pH 8, 150 mM NaCl, 1
mM DTT and subjected to sparse matrix screening in sitting drops at 17˚C. Crystals grew reproduc-
ibly in 10 % w/v PEG 4000, 20% v/v glycerol, 0.03 M diethylene glycol, 0.03 M trithylene glycol, 0.03
M tetraethylene glycol, 0.03 M pentaethylene glycol, 0.055 M MES, 0.045 M Imidazole, pH 6.5. The
crystals were cryoprotected in 20% Ethylene Glycol and flash frozen in liquid Nitrogen. Diffraction
experiments were performed at the Diamond light source on the I04-1 beamline, which was
equipped with a PILATUS 2M detector. A 1.95 Å resolution data set was collected at a wavelength
of 0.92 Å. TRIM21RING-Box protein contained four zinc atoms per monomer, allowing for the collec-
tion of SAD data. Data indexing and scaling were performed with MOSFLM and AIMLESS
respectively (Winn et al., 2011). Experimental phasing, density modification and initial model
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building was performed using AutoSol from the PHENIX suite (Adams et al., 2010). Further model
building was performed in Coot (Emsley and Cowtan, 2004). REFMAC 5.7 was used for model
refinement, with initial rounds of restrained refinement including phase information from Hendrick-
son-Lattman coefficients (Murshudov et al., 1997). In later rounds, Translation/liberation/screw
(TLS) refinement was introduced with individual polypeptide chains defined as TLS groups. MolPro-
bity, which was used for model validation, gave ramachandran statistics of: 95.2% of residues were
found in favoured regions and 100% in allowed regions (Chen et al., 2010). The structure factors
and coordinates can be found in the Protein Data Bank, with the accession number 5OLM.
NMR spectroscopy
13C/15N or 15N isotopically labelled TRIM21 proteins were buffer exchanged into 50 mM [2H11]-tris,
pH 7.0, 150 mM NaCl, 1 mM [2H10]-DTT, H2O/
2H2O 95:5. Spectra were recorded at 25˚C on Bruker
DRX 500 and Avance I 600 spectrometers (Bruker BioSpin GmbH), each equipped with a
(1H/15N/13C) 5 mm cryoprobe, and were processed using the program Topspin (Bruker BioSpin
GmbH) and analysed using the program Sparky (Goddard). Assignments were made using 13C/15N
labelled protein and a standard suite of NMR experiments ([15N,1H] HSQC, [13C,1H] HSQC, HNCA,
HNCOCA, CBCANH, CBCA(CO)NH, HBHANH and HBHA(CO)NH), allowing 93% of TRIM21RING-
M10E, 97% of TRIM21RING-Box-M10E and 95% of TRIM21RING-Box-M10E/S80E amide resonances of non-
proline residues to be assigned. Chemical shift perturbations (CSPs) were measured using samples
of 15N-labelled 90 mM TRIM21RING-M10E, 200 mM TRIM21RING-Box-M10E or 200 mM TRIM21RING-Box-
M10E/S80E, to which were added either 0.5 or 1 molar equivalents of unlabeled Ube2N; the reported
CSP values are all for 1:1 complexes and were calculated according to the formula ((Dd(1H))2 +
(Dd(15N)/5)2)1/2.
Relaxation analysis
15N{1H} heteronuclear NOE ratios for the amide signals of TRIM21RING-Box-M10E and TRIM21RING-Box-
M10E/S80E were measured using 200 mM 15N labelled samples and a pre-saturation time of 7 s, essen-
tially as described by (Skelton et al., 1992).
Solvent PRE
Solvent paramagnetic relaxation enhancement (PRE) data were measured by the addition of the sol-
uble contrast agent, Gd-DTPA. A 100 mM stock solution of Gd-DTPA was made in 50 mM [2H11]-tris
and the pH adjusted to 7.0; this solution was added to a final concentration of 4 mM to samples of
200 mM TRIM21RING-Box-M10E or 200 mM TRIM21RING-Box-M10E/S80E. Peak intensities for each amide
signal in the [15N,1H] HSQC spectra were recorded before (IREF) and after (IPRE) addition of the con-
trast agent; for Figures 4H and 6, the reported PRE ratio is calculated as ([IPRE/IREF]WT)/([IPRE/IREF]
S80E).
Acknowledgements
This work was funded by the Medical Research Council (UK; U105181010 and U105178934) and a
Wellcome Trust Investigator Award. We thank Dr. Jonathan Pruneda for assistance with E2 discharge
assays. CFD was supported by an NHMRC Early Career Fellowship (APP1110116).
Additional information
Funding
Funder Grant reference number Author





Medical Research Council U105181010 David Neuhaus
Leo C James
Medical Research Council U105178934 David Neuhaus
Wellcome Trust 200594/Z/16/Z Leo C James
Dickson et al. eLife 2018;7:e32660. DOI: https://doi.org/10.7554/eLife.32660 19 of 22
Research article Structural Biology and Molecular Biophysics
The funders had no role in study design, data collection and interpretation, or the
decision to submit the work for publication.
Author contributions
Claire Dickson, Data curation, Formal analysis, Investigation, Writing—review and editing, Conceived
the project and wrote the manuscript, Performed X-ray crystallography and in vitro ubiquitination
assays; Adam J Fletcher, Formal analysis, Investigation, Writing—review and editing, Conceived the
project and wrote the manuscript, Carried out cellular experiments and kinase assays; Marina Vays-
burd, Investigation, Carried out virus-induced cytokine infections; Ji-Chun Yang, Investigation, Per-
formed NMR experiments; Donna L Mallery, Investigation, Assisted with ubiquitination assays;
Jingwei Zeng, Investigation, Assisted with cell experiments, Provided new reagents; Christopher M
Johnson, Investigation, Performed multi-angle light scattering; Stephen H McLaughlin, Investigation,
Performed AUC; Mark Skehel, Supervision; Sarah Maslen, Investigation; James Cruickshank, Supervi-
sion, Investigation; Nicolas Huguenin-Dezot, Methodology; Jason W Chin, Supervision, Methodol-
ogy; David Neuhaus, Data curation, Supervision, Analysed and supervised NMR; Leo C James,
Conceptualization, Formal analysis, Supervision, Writing—original draft, Writing—review and edit-
ing, Conceived the project and wrote the manuscript
Author ORCIDs
Stephen H McLaughlin https://orcid.org/0000-0001-9135-6253
Leo C James https://orcid.org/0000-0003-2131-0334





. Supplementary file 1. Data collection and refinement statistics
DOI: https://doi.org/10.7554/eLife.32660.017
. Supplementary file 2. Solvent PRE raw data
DOI: https://doi.org/10.7554/eLife.32660.018
. Transparent reporting form
DOI: https://doi.org/10.7554/eLife.32660.019
References
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